Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
- 1 May 2019
- journal article
- review article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 51 (5) , 632-639
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapyAnnals of the Rheumatic Diseases, 2017
- Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide CohortJournal of Crohn's and Colitis, 2015
- Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single centerExpert Opinion on Biological Therapy, 2015
- Biosimilars: the science of extrapolationBlood, 2014
- Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel DiseaseDigestive and Liver Disease, 2014
- Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case SeriesDigestive Diseases and Sciences, 2014
- The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paperAutoimmunity Reviews, 2014
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS studyAnnals of the Rheumatic Diseases, 2013
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA studyAnnals of the Rheumatic Diseases, 2013
- Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel diseaseRevista Española de Enfermedades Digestivas, 2013